Tag Archives: pulmonary arterial hypertension

November, 2018

October, 2018

September, 2018

August, 2018

January, 2018

September, 2017

July, 2017

  • 12 July

    Arena Pharmaceuticals’ Ralinepag Demonstrates Positive Results in Mid-Stage PAH Study

    SAN DIEGO, July 10, 2017 /PRNewswire/ — Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced positive Phase 2 results for ralinepag, an investigational, long-acting, orally administered prostacyclin receptor agonist under development for the treatment of pulmonary arterial hypertension (PAH).  In this 61-patient study, the primary efficacy analysis demonstrated a statistically significant absolute change from baseline in …

June, 2017

October, 2016

December, 2015

  • 28 December

    FDA Approves Actelion’s Uptravi for Pulmonary Arterial Hypertension

    ALLSCHWIL, SWITZERLAND – 22 December 2015 – Actelion (SIX: ATLN) announced today that the United States Food and Drug Administration (FDA) has approved the use of the orally active, selective IP prostacyclin receptor agonist Uptravi (selexipag), originally discovered and synthesized by Nippon Shinyaku, for the treatment of pulmonary arterial hypertension …